 Glucagon-Like Peptide 1
"Glucagon-Like Peptide 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
| Descriptor ID |
D052216
|
| MeSH Number(s) |
D06.472.317.469.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide 1".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide 1".
This graph shows the total number of publications written about "Glucagon-Like Peptide 1" by people in this website by year, and whether "Glucagon-Like Peptide 1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2008 | 1 | 1 | 2 | | 2009 | 2 | 1 | 3 | | 2010 | 2 | 1 | 3 | | 2011 | 3 | 3 | 6 | | 2012 | 2 | 0 | 2 | | 2013 | 3 | 3 | 6 | | 2014 | 7 | 2 | 9 | | 2015 | 3 | 3 | 6 | | 2016 | 1 | 2 | 3 | | 2017 | 4 | 2 | 6 | | 2018 | 1 | 0 | 1 | | 2019 | 3 | 4 | 7 | | 2020 | 4 | 1 | 5 | | 2021 | 1 | 1 | 2 | | 2022 | 2 | 3 | 5 | | 2023 | 1 | 4 | 5 | | 2024 | 2 | 1 | 3 | | 2025 | 2 | 7 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucagon-Like Peptide 1" by people in Profiles.
-
Cherney DZI, Belmar N, Bjornstad P, Chacko MM, Gunnarsson TP, Hodgin JB, Kretzler M, Pruijm M, Schytz PA, Tuttle KR. Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2025 Oct 30; 40(11):2182-2192.
-
Rasouli N, Guder Arslan E, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Sourij H, Thomas S, Verma S, Bonaca MP. Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial. Diabetes Care. 2025 Sep 01; 48(9):1529-1535.
-
Shah VN, Akturk HK, Kruger D, Ahmann A, Bhargava A, Bakoyannis G, Pyle L, Snell-Bergeon JK. Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evid. 2025 Aug; 4(8):EVIDoa2500173.
-
Lindsay M, Arndt G, Wieland A, Jensen T. Evolving Role of GLP-1 Therapies in Liver Disease. Curr Gastroenterol Rep. 2025 Jun 06; 27(1):36.
-
Bonaca MP, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Ramesh CK, Rasouli N, Sourij H, Videmark A, Verma S. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025 05 03; 405(10489):1580-1593.
-
Ditzenberger GL, Lake JE, Kitch DW, Kantor A, Muthupillai R, Moser C, Belaunzaran-Zamudio PF, Brown TT, Corey K, Landay AL, Avihingsanon A, Sattler FR, Erlandson KM. Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study. Clin Infect Dis. 2025 02 24; 80(2):389-396.
-
Muschler K, Muschalek R, Hoyte C. Characterization of glucagon-like peptide-1 (GLP-1) agonist exposures reported to a single United States poison center. Clin Toxicol (Phila). 2025 Feb; 63(2):133-136.
-
Bonaca MP, Catarig AM, Hansen Y, Houlind K, Ramesh CK, Ludvik B, Nordanstig J, Rasouli N, Sourij H, Verma S. Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes. Eur Heart J Cardiovasc Pharmacother. 2025 Jan 11; 10(8):728-737.
-
Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 Jan; 27(1):1-9.
-
O'Donnell C, Ryan O, Hogan AE, Killick D, Crilly S, Dodd JD, Murphy DJ, Ryan S, O'Shea D. GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea. Obesity (Silver Spring). 2024 Nov; 32(11):2077-2081.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|